Yttrium (90Y) tacatuzumab tetraxetan
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | α-fetoprotein |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6470H9971N1712O2007S4290Y |
| Molar mass | 145 kg/mol |
  (what is this?) (verify) | |
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council". 4 September 2004. Archived from the original on 2004-09-11.
- WHO Drug Information
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.